• Revenues relatively flat at $10.1 million, down 4.9% from prior year
• Loss before tax improved to $2.9 million, down from $9.6 million in prior year
• Cost reduction initiatives delivered $3.2 million in savings

Hydrix Limited reported its FY25 financial results, with revenues relatively flat at $10.1 million, down 4.9% from the prior year. The company's Hydrix Services business, which provides product design and development consulting services, generated the majority of the revenue and operating costs. Hydrix Medical, which distributes disruptive cardiovascular products, and Hydrix Ventures, which invests in high-potential medtech clients, also contributed to the group's operations. The consolidated entity loss before income tax decreased significantly to $2.9 million, down from $9.6 million in the prior year. This improvement was primarily attributable to $3.2 million in cost reduction initiatives, including a reduction in rental overheads and employee costs. The company's Hydrix Services business sustained strong progress building its international medtech client base, generating 63% of its revenues from outside Australia. However, many of Hydrix's clients are emerging medtech start-ups reliant on raising venture capital, and fund-raising conditions have been challenging, leading to longer sales cycles. Hydrix Ventures' portfolio of investments in high-potential medtech clients increased in value by $0.15 million during the year. The company's cash position at 30 June 2025 was $0.30 million, with additional funds available under a $2 million shareholder letter of comfort.